Promising Advancements in Jasper Therapeutics’ Briquilimab Programs Highlight Market Potential

In a report released today, Emily Bodnar from H.C. Wainwright maintained a Buy rating on Jasper Therapeutics (JSPR – Research Report), with a price target of $40.00.

Emily Bodnar’s rating is based on Jasper Therapeutics’ promising progress in their briquilimab programs, which are advancing through various clinical stages. The company has shown significant development in its Phase 1a/2b studies for chronic spontaneous urticaria and allergic asthma, with upcoming data expected to provide further insights into the drug’s efficacy and safety.
Additionally, the completion of enrollment in the SPOTLIGHT study and the anticipated presentation of updated data at the EAACI annual congress highlight the potential of briquilimab in treating cold urticaria and symptomatic dermographism. The favorable safety profile observed in early trials supports the initiation of a Phase 2b study, with dose selection informed by mid-2025 data. This strategic approach, coupled with the potential differentiation of dosing regimens, positions Jasper Therapeutics favorably in the market.